ACM
SAGE

Altium Capital Management’s Sage Therapeutics SAGE Stock Holding History

Altium Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,000
Closed -$1.91M – 106
2022
Q4 		$1.91M Buy
+50,000
New +$1.91M 0.97% 38
2022
Q3 		– Sell
-15,000
Closed -$485K – 153
2022
Q2 		$485K Buy
+15,000
New +$503K 0.19% 96

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Altium Capital Management's SAGE Position: Q1 2023 in Review

Altium Capital Management sold out of Sage Therapeutics (SAGE) in Q1 2023, closing a stake of 50,000 shares — an estimated $1.91M sold.

Altium Capital Management first reported a position in SAGE in Q2 2022 and held it in 2 quarters. The position peaked at $1.91M in Q4 2022. 213 funds tracked by Wall St. Rank hold SAGE as of Q1 2023.

  • Altium Capital Management reported no remaining Sage Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Altium Capital Management sold 50,000 Sage Therapeutics shares in Q1 2023, an estimated $1.91M.
  • Altium Capital Management first reported a position in Sage Therapeutics in Q2 2022 and held it in 2 quarters.
  • Altium Capital Management's Sage Therapeutics position peaked at $1.91M in Q4 2022.
  • 213 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2023.

Based on Altium Capital Management's 13F filing for Q1 2023, filed 15 May 2023.